Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated
Open Access
- 17 June 2015
- journal article
- research article
- Published by Springer Nature in BMC Medical Genetics
- Vol. 16 (1) , 39
Abstract
Mutations in TSC1 or TSC2 cause the tuberous sclerosis complex (TSC), while mutations in PKD1 or PKD2 cause autosomal dominant polycystic kidney disease (ADPKD). PKD1 lays immediately adjacent to TSC2 and deletions involving both genes, the PKD1/TSC2 contiguous gene syndrome (CGS), are characterized by severe ADPKD, plus TSC. mTOR inhibitors have proven effective in reducing angiomyolipoma (AML) in TSC and total kidney volume in ADPKD but without a positive effect on renal function. We describe a patient with independent truncating PKD1 and TSC2 mutations who has the expected phenotype for both diseases independently instead of the severe one described in PKD1/TSC2-CGS. Treatment with mTOR inhibitors reduced the AML and kidney volume for 2 years but thereafter they resumed growth; no positive effect on renal function was seen throughout. This is the first case addressing the response to mTOR treatment when independent truncating mutations in PKD1 and TSC2 are present. This case reveals that although PKD1 and TSC2 are adjacent genes and there is likely cross-talk between the PKD1 and TSC2 signalling pathways regulating mTOR, having independent TSC2 and PKD1 mutations can give rise to a milder kidney phenotype than is typical in PKD1/TSC2-CGS cases. A short-term beneficial effect of mTOR inhibition on AML and total kidney volume was not reflected in improved renal function.Keywords
This publication has 48 references indexed in Scilit:
- Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trialOrphanet Journal of Rare Diseases, 2012
- Primer3—new capabilities and interfacesNucleic Acids Research, 2012
- Inhibition of MTOR Disrupts Autophagic Flux in PodocytesJournal of the American Society of Nephrology, 2012
- Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels DecreasePLOS ONE, 2011
- Carboxy Terminal Tail of Polycystin-1 Regulates Localization of TSC2 to Repress mTORPLOS ONE, 2010
- mTOR signaling at a glanceJournal of Cell Science, 2009
- Polycystin-1 Regulates Extracellular Signal-Regulated Kinase-Dependent Phosphorylation of Tuberin To Control Cell Size through mTOR and Its Downstream Effectors S6K and 4EBP1Molecular and Cellular Biology, 2009
- Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndromeKidney International, 2008
- The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathwayHuman Molecular Genetics, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008